Yifan Li

China

Dr Li has ertise in management and passion in improving the prognosis and quality of life of patients of gastric cancer.

Member of Shanxi Anti-Cancer Association.

Natalia Neparidze

USA

Dr. Neparidze serves as an Associate Professor and the leader of Yale Myeloma Research team. She has developed multiple research projects in myeloma, including a number of investigator-initiated therapeutic clinical trials. She serves as a PI and co-PI on multiple therapeutic clinical trials and leads several clinical outcomes studies in patients with myeloma. Her ongoing research directions include use of advanced imaging and evaluating tumor heterogeneity to enhance precision medicine approaches for myeloma, novel combination immunotherapy strategies and MRD-driven therapies in myeloma, as well as studying biology and clinical outcomes of monoclonal gammopathies in association with metabolic, viral and other co-morbidities, investigating mechanisms of tumor progression and resistance in myeloma.

Shunfu Hu

USA

Dr. Shunfu Hu is a Professor of Geography and Geograohic Information Sciences, Southern Illinois University Edwardsville, USA. He has recently worked on public health data sets for the purpose of visualizing the spatiotemporal patterns of the morality rates of many diseases, including cancer.

Jagadananda Ghosh

USA

Dr. Ghosh is a Senior Scientist at the Henry Ford Hospital in Detroit, Michigan, USA. The primary focus of his research is to understand the mechanisms underlying resistance to anticancer therapies. Recently, his team made a groundbreaking observation that the Tribbles 2 pseudokinase confers resistance to anti-androgens by driving neuroendocrine trans-differentiation. He is keenly interested to explore downstream mechanisms of Tribbles 2 and develop novel agents to overcome therapeutic resistance by targeting Tribbles 2. Dr. Ghosh is an internationally renowned scientist and would like to share recent results related to mechanism-based development of a new therapy for aggressive, drug-resistant, lethal prostate cancer.

Anne-Catherine Prats

France

Anne-Catherine PRATS has international reputation in the field of RNA and translational control, and received several scientific prizes. She has focused on the role of mRNA IRESs, non-coding RNAs and RNA-binding proteins in the control of gene expression in stress conditions. She has studied the impact of these molecular mechanism in cancer development as well as in cardiovascular diseases. ACP is also an expert in vectorology and gene therapy and is presently focusing on lymphedema gene therapy in the THERALYMPH European consortium.